30 results about "ERYTHROCYTES AGGLUTINATION" patented technology

A cell analyzer, an erythrocyte agglutination warning method and an erythrocyte agglutination warning system of the cell analyzer. The erythrocyte agglutination warning method includes following steps: (1) measuring volume information of cells in a sample; (2) recognizing the cells of which the volume information is larger than a preset volume threshold value to obtain an agglutinated erythrocyte group; (3) counting the number of the cells in the agglutinated erythrocyte group to obtain an agglutinated erythrocyte amount; (4) determining whether the agglutinated erythrocyte amount is large than a preset number threshold value, and if the agglutinated erythrocyte amount is large than the preset number threshold value, carrying out erythrocyte agglutination warning. Determination on the content of certain components in the cells is unnecessary since the agglutinated erythrocyte is recognized directly according to the volume of the cells, so that compared with a conventional erythrocyte agglutination warning method, the method can improve a warning accuracy and is simple, convenient and quick.

The invention discloses a recombinant galactose agglutinin-1 two-string protein and a preparation method thereof. The method specifically comprises the following steps of: providing a recombinant Galectin-1 protein with bioactivity through a biotechnological method; respectively transfecting BL21 to construct engineering bacteria through constructing prokaryotic expression vectors pET-22b(+)-Gal-1 and pET-22b(+)-Gal-1 (2); and then obtaining the recombinant Galectin-1 monomer protein or a recombinant Galectin-1 two-string protein through IPTG (Isopropyl Beta-D-1-Thiogalactopyranoside) induction expression and the chromatographic separation and passivation after dividing the bacteria. Through an erythrocyte agglutination test, it is proved that both the two recombinant Galectin-1 proteins have obvious bioactivity, and the bioactivity of the Galectin-1 two-string protein is higher than that of the Galectin-1 monomer protein.

The invention belongs to the technical field of microbiological detection, and discloses an influenza hemagglutination inhibition test detection method which comprises the following steps: pretreatingstandard reference antiserum to remove non-specific inhibin and non-specific lectin in the serum; preparing an erythrocyte suspension; determining the hemagglutination titer of the influenza virus strain; preparing four hemagglutination unit antigens for an erythrocyte agglutination inhibition test; rechecking and titrating four hemagglutination unit antigens; and performing influenza virus identification and antigen analysis by using an HAI method to obtain the serum titer of the detected serum. According to the detection method, chicken erythrocyte, turkey erythrocyte and guinea pig erythrocyte are used as raw materials to prepare erythrocyte suspension, animal erythrocyte is used for replacing human erythrocyte, and the difficulty that an experiment cannot be conducted due to lack of erythrocyte is solved.

The invention discloses a novel coronavirus COVID-2019 detection card and a preparation method thereof. The novel coronavirus COVID-2019 detection card comprises a card supporting layer attached to detection test paper, a sample unit positioned on the card supporting layer, a preprocessing unit positioned on the card supporting layer, a marker unit positioned on the card supporting layer, a detection unit positioned on the card supporting layer, and a recycling unit positioned on the card supporting layer; the sample units correspond to the sample holes; the pretreatment unit corresponds to the pretreatment hole; a hollow or transparent sealed detection window is arranged at the position, corresponding to the detection unit, of the shell; the erythrocyte agglutination layer is provided with erythrocyte agglutinin; the endogenous interfering substance treatment layer is provided with an endogenous interfering substance conjugate; the exogenous interfering substance treatment layer is provided with an exogenous interfering substance chelating agent; a non-specific IgM antibody treatment layer is provided with an IgM chelating agent; a non-specific IgG antibody treatment layer has anIgG precipitant. The problem that interfering substances influence the detection result of the novel coronavirus is solved, and the detection accuracy is improved.

The invention relates to active polypeptide and a gene thereof, and application of the active polypeptide to pharmacy. Microhyla pulchra antioxidation peptide is cyclopeptide consisting of 12 pieces of amino acid, wherein the molecular weight is 1334.91 daltons; the isoelectric point is 8.002; the amino acid sequence is SEQ ID NO.1; and the third-position cysteine and the eleventh-position cysteine of the polypeptide form intramolecular disulfide bonds. The gene sequence of the microhyla pulchra antioxidation peptide consists of SEQ ID NO.4, and the gene encoded with the functional mature microhyla pulchra antioxidation peptide is the 187th to the 222nd position nucleotide. The gene of the microhyla pulchra antioxidation peptide deduces the mature functional polypeptide amino acid sequence, and the synthesized microhyla pulchra antioxidation peptide has strong erythrocyte agglutination and anti-oxidation functions.

The invention belongs to the technical field of veterinary drugs, and particularly relates to a Newcastle disease attenuated sugar vitrified vaccine and a preparation method thereof. The preparation raw materials of the vaccine include hatching eggs, reagents and seed virus. The reagents comprise any one or more of PBS (phosphate buffer solution) or normal saline and any one or more of a penicillin solution or a streptomycin solution; and the seed virus comprises any one or more of an HB1 strain, an F strain, a LaSota strain, a LaSota-Clone30 strain or an N79 strain, and propiolactone. The vaccine also comprises a raw material reactant for preparing the vitrified vaccine, and the reactant is specifically one or more of trehalose or agarose. According to the present invention, an erythrocyte experiment is directly performed on the generated vaccine, and the optimal attenuated virus can be found according to the optimal erythrocyte agglutination point so as to effectively ensure the performance of the vaccine.